Physician profile
Keith Horner
NPI 1235103334
$3,099.48
in general payments reported to CMS, 2019-2025
29 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $53.60 · 2021: $87.78 · 2022: $174 · 2023: $237 · 2024: $351 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.78 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $774.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $198.90 | 2019-2025 | |
| Lilly USA, LLC | $187.39 | 2019-2025 | Kisunla, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $177.80 | 2019-2025 | Arexvy, Shingrix |
| Amgen INC. | $171.07 | 2019-2024 | Repatha |
| Abbvie INC. | $156.69 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $152.72 | 2024-2025 | Zoryve |
| Amarin Pharma, INC. | $119.60 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $119.01 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Dexcom, INC. | $117.78 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $117.51 | 2019 | |
| Medtronic, INC. | $116.53 | 2025 | Abre |
| Ironshore Pharmaceuticals INC. | $107.42 | 2019 | |
| Supernus Pharmaceuticals, INC. | $87.78 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.34 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.70 | 2019 | |
| Allergan, INC. | $54.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $52.85 | 2019-2025 | |
| Axsome Therapeutics, INC. | $52.39 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $30.67 | 2025 | Voquezna |
| Cochlear Americas | $29.75 | 2024 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Inspire Medical Systems, INC. | $16.47 | 2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.33 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $15.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.80 | 2019 | |
| Shire North American Group INC | $13.93 | 2019 | |
| Merck Sharp & Dohme LLC | $13.61 | 2019 | |
| Organon LLC | $11.61 | 2025 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Horner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.